A mutation present in around half of malignant melanomas has been confirmed as a strong drug target, according to research published in Science Translation Medicine. The study was conducted by The Institute of Cancer Research (ICR) and funded by the Wellcome Trust, Cancer Research UK and the ICR. Several drugs that target the BRAF mutation have already reached clinical trial in patients with this deadly form of skin cancer, and some are showing promising results. However, it has not been clear whether their effectiveness was from inhibiting BRAF as designed or for another reason...
More...
More...